“…Over the years, our group and others have made significant contributions towards the development of pharmacological neuroimaging-ie, the use of neuroimaging-based measures to determine target engagement and modulation of brain networks and mechanisms relevant to acute and chronic pain across different classes of compounds. 11,28,58,67,69,85,95,98,114,128,[133][134][135] Subjective ratings of pain and analgesia are influenced by many factors, as we have shown perhaps most strikingly in an earlier study. 9 Therefore, obtaining early information that a drug has target engagement and some efficacy against the mechanism being targeted in human experimental medicine models or patients, irrespective of the analgesic rating, is valuable and can hopefully lead to fewer good drugs being falsely failed and more poorer drugs being stopped earlier in analgesic drug development.…”